Over the last 12 months, Relay Therapeutics insiders reported no purchases and 9 sales totaling $7.2M across SEC Form 4 filings. 67% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 1,459 | $18.61 | $27K | -0.9% | — |
| Jul 28, 2026 | Rahmer PeterSee remarks · O | ▼ Sale | 748 | $18.61 | $14K | -0.3% | — |
| Jul 28, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 2,237 | $18.61 | $42K | -0.5% | — |
| Jul 7, 2026 | Patel SanjivPresident and CEO · O·D | ▼ Sale | 48,199 | $19.58 | $944K | -7.3% | plan |
| Jul 6, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 8,660 | $18.71 | $162K | -2.1% | plan |
| Jul 6, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 17,717 | $18.69 | $331K | -10% | plan |
| Jun 30, 2026 | Rahmer PeterSee remarks · O | ▼ Sale | 50,000 | $19.09 | $955K | -18.1% | plan |
| Jun 22, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 187,163 | $16.97 | $3.2M | -51.3% | plan · 4 tranches |
| Jun 22, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 93,456 | $16.94 | $1.6M | -18.3% | plan |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RLAY feed.